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CASE REPORT
A 45-year-old man presented with progressing dyspnea 
and pain in the right shoulder for 1 month. His only medical 
history was an episode of deep vein thrombosis in the right 
arm 10 years earlier. He was a smoker with estimated 15 
pack-years. He worked as a truck driver and had no history of 
asbestos exposure. A physical examination by his general prac-
titioner revealed decreased breath sounds over the right lung.
A subsequent chest radiograph revealed a large pleural 
effusion in the right pleural cavity. On pleuracentesis 3300 ml 
of bloody pleural effusion was drained. Bacteriology was neg-
ative and cytology revealed no malignant cells.
A computed tomography of thorax and abdomen showed 
several irregular pleural plaques resembling malignant pleural 
mesothelioma (MPM). No enlarged lymph nodes were seen. A 
whole-body positron emission tomography–computed tomog-
raphy showed increased 18F-fluorodeoxyglucose uptake in 
the pleura of the right hemithorax and in lymph nodes of the 
mediastinum and the retroperitoneum, as seen in Figure 1. 
During the subsequent thoracoscopy red and white swollen 
changes were seen in both parietal and visceral pleura.
Pathology
Pleural biopsies revealed round/polygonal tumor cells in 
a solid or diffuse pattern with moderate amounts of eosinophilic 
cytoplasm and central but focally eccentric pleomorphic nuclei 
(rhabdoid characteristics) with prominent nucleoli and finely 
granulated chromatin (Fig. 2). Immunostains were strongly posi-
tive to mesenchymal vimentin and epithelial pancytokeratin KL-1 
and CK8 antigens combined with positive CD34 and loss of INI-
1. A focal reaction was noticed to EP4, EMA, CK20, SMA and 
cytoplasmic WT-1. There was no reaction to the following epi-
thelial markers: carcinoembryonic antigen (CEA), cytokeratin 7 
(CK7), thyroid transcription factor-1 (TTF-1), cytokeratin 5 and 
6 (CK5/6), tumor protein 63 (P63), homeobox protein CDX-2 
(CDX-2), Hep Par-1 (HEP-1), renal cell carcinoma (RCC), clus-
ter of differentiation 10 (CD10), to specific mesothelial markers 
Calretinin, HBME1, WT-1 (nuclear), D2-40, or to the endothe-
lial markers CD31 and Fli-1, the muscle marker Desmin, the 
melanoma markers: S-100, Melan-A, human melanoma black-
45 (HMB-45), microphtalmia associated transcription (MITF), 
the germ cell tumor markers alpha-fetoprotein (AFP), placental 
alkaline phosphatase (PLAP), human chorionic gonadotropin 
(HCG), Inhibin, HPL, or the neuroendocrine markers CD56, 
Chromogranin-A (synaptofycin showed very weak nonspecific 
focal staining), CD99, CD30, CD117, or Bcl-2. Fluorescent in 
situ hybridization for deletion of the cyclin-dependent kinase 
inhibitor 2A (CDKN2A) gene was negative.
This patient showed symptoms only 1 month before 
admission. His condition rapidly deteriorated and 2 months 
later he was admitted to a hospice and died within 1 week.
DISCUSSION
These morphological characteristics, immunohistochemis-
try (IHC), and molecular biology were consistent with epithelioid 
sarcoma of proximal type, rather than mesothelioma, carcinoma, 
angiosarcoma, or synovial sarcoma.1–3 A search in PubMed with 
key words pleural tumor, epithelioid sarcoma, and pleural sarcoma 
revealed no other cases of primary pleural epithelioid sarcoma.
As a primary in the pleura this is extremely unusual, 
but perhaps underdiagnosed. Because of its involvement of 
the whole right pleura and no evidence of a primary tumor 
anywhere else, we consider it to be a primary in the pleura.
With improved diagnostic tools such as IHC, we might in 
the future see more cases of pleural epithelioid sarcoma in the 
pleura, which might in the past have been diagnosed as MPM. 
In clinical practice this will affect our course of treatment.
MPM and sarcomas do not respond to the same treat-
ment. Cisplatin and pemetrexed are the first-line treatment for 
MPM, whereas doxyrubicin is first-line for treating sarcomas. 
Second and third lines also differ.
A correct diagnosis is essential for choosing the right 
treatment and obtaining the best outcome for the patient. With 
more extensive use of IHC and molecular pathology we can 
improve our diagnostic precision and thus offer our patients 
the best treatment.
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FIGURE 1.  Positron emission tomography–computed tomography showing increased 18F-fluorodeoxyglucose uptake in the 
pleura in the right hemithorax, lymph nodes in the mediastinum and retroperitoneum.
FIGURE 2.  Standard hematoxylin and eosin (H&E) and immunostainings for integrase interactor 1 (INI-1), antipancytokeratin 
(KL-1), epithelial membrane antigen (EMA), and cluster of differentiation (CD34). All at high power (×400).
